Efficacy and safety of canagliflozin in patients with type 2 diabetes: A meta-analysis of randomized controlled trials

BACKGROUND: Canagliflozin is a new SGLT2 inhibitor which has been approved as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes (T2D) mellitus in more than 30 countries. To evaluate the efficacy and safety of canagliflozin in patients with T2D, we carried out a meta-an...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Wei, Xiao, Ming Yue, Zhang, Mei, Chang, Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
4400
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134817/
https://www.ncbi.nlm.nih.gov/pubmed/27902600
http://dx.doi.org/10.1097/MD.0000000000005473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134817/
https://www.ncbi.nlm.nih.gov/pubmed/27902600
http://dx.doi.org/10.1097/MD.0000000000005473

Ejemplares similares